Acceptability: total withdrawals · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher ACR 50% improvement compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
DAS (low or remission) · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review